Stockscreener 앱 받기
0.8452
9.13%
-0.0849
시간 외 거래:
.85
0.0048
+0.57%
전일 마감가:
$0.9301
열려 있는:
$0.91
하루 거래량:
160.41K
Relative Volume:
0.37
시가총액:
$10.47M
수익:
$285.80K
순이익/손실:
$-12.60M
주가수익비율:
-0.4281
EPS:
-1.9743
순현금흐름:
$-13.44M
1주 성능:
-9.15%
1개월 성능:
-15.48%
6개월 성능:
-28.97%
1년 성능:
-54.56%
1일 변동 폭
$0.8289
$0.91
1주일 범위
$0.8289
$1.0015
52주 변동 폭
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.8452 | 11.52M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com
[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks
Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo
Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo
Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart
Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress - TipRanks
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher - ChartMill
Aprea Therapeutics (NASDAQ: APRE) trims Q1 loss and raises over $34M to extend cash runway - Stock Titan
APREA THERAPEUTICS ($APRE) Releases Q1 2026 Earnings - Quiver Quantitative
Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary - TradingView
Aprea Therapeutics Reports Q1 2026 Results: $30M Financing Boosts APR-1051 Clinical Progress and Extends Cash Runway to 2028 - Minichart
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 Trial - Quiver Quantitative
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall - TradingView
Aprea (NASDAQ: APRE) extends cash runway and reports Q1 2026 results - Stock Titan
Early tumor responses and $30M cash boost for Aprea cancer drug - Stock Titan
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech - Barchart.com
TradingKey - TradingKey
APRE (Aprea) beats Q4 earnings by 20%, but shares fall 2.3% amid growth concerns.Community Breakout Alerts - newser.com
APRE (Aprea) Q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%.Put/Call Ratio - newser.com
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target - marketscreener.com
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com Nigeria
APRE | Aprea Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
APRE Stock Price, Quote & Chart | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
Reverse split and director votes in Aprea Therapeutics (NASDAQ: APRE) 2026 proxy - Stock Titan
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
74.35M shares registered for resale by Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
CatalYm picks ex-Aprea CEO Christian Schade to chair board - Stock Titan
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study - MyChesCo
Aprea Therapeutics (NASDAQ: APRE) reporting group discloses 9.9% stake - Stock Titan
Two life sciences companies with Doylestown connections raise $119M - MSN
APRE Forecast, Price Target & Analyst Ratings | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
Aprea (APRE): Buy, Sell, or Hold? | Q4 2025: EPS Beats ForecastsEV/EBITDA - Xã Vĩnh Công
Aprea Therapeutics (NASDAQ: APRE) registers 74.35M shares for resale by investors - Stock Titan
Greater Philadelphia-based Aprea Therapeutics Raises $30M to Extend Runway and Reposition Its Precision Oncology Bet - biobuzz.io
Aprea Therapeutics abstract accepted at ASCO meeting in May - Investing.com
Aprea Therapeutics abstract accepted at ASCO meeting in May By Investing.com - Investing.com Canada
Aprea Therapeutics Announces Acceptance of Abstract for Phase 1 Study of WEE1 Inhibitor APR-1051 at ASCO 2026 - Quiver Quantitative
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting - Weekly Voice
Early human data on Aprea cancer drug lands ASCO 2026 poster slot - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) seeks board authority for 1‑for‑3–1‑for‑8 reverse split - Stock Titan
Aprea reports partial response in APR-1051 cancer trial - MSN
Aprea (APRE) Stock: Why It Matters Now (Eye on Rally) 2026-04-18Blue Chip Stocks - Xã Thanh Hà
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.53%
자본화:
|
볼륨(24시간):